News Related to Small Molecule Inhibitors

Related coverage linked through entity extraction aliases.

Pediatric Cancer Drug Development Lags Behind Adult Approvals, Study Finds

May 15, 2026

Only 17.7% of pediatric anticancer drugs advance to phase 3 trials, and just 12% earn FDA approval within 10 years, compared to 38.7% for adult drugs. The pace of pediatric approvals has accelerated recently, but funding and market size constraints remain.

Australian Universities Advance AI and Quantum Drug Discovery Platforms

Mar 03, 2026

University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.